Oncology company Novocure (NASDAQ: NVCR) announced on Wednesday the success of its phase 3 METIS clinical trial, revealing a significant improvement in time to intracranial progression for non-small cell lung cancer (NSCLC) patients treated with Tumor Treating Fields (TTFields) therapy alongside supportive care.

Patients experienced a median time to intracranial progression of 21.9 months, compared to 11.3 months for those receiving supportive care alone. The treatment was well-tolerated with sustained quality of life and neurocognitive function.

METIS, involving 298 patients, demonstrated the efficacy of TTFields therapy in treating 1-10 brain metastases from NSCLC post-stereotactic radiosurgery.

Novocure intends to submit the data to regulatory authorities and publish findings in a peer-reviewed journal.

Brain metastases are common in NSCLC patients, affecting quality of life and prognosis. TTFields therapy offers a promising treatment option with minimal neurocognitive adverse events.